2024/07/16 08:02:11 | |
---|---|
Price | |
12.22 EUR | |
Difference | -1.77% (-0.22) |
ISIN | BE0003766806 |
Symbol | IBAB |
Exchange | Frankfurt |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 365 EUR |
Benchmark | BEL 20 INDEX |
Bid (Bid size) | 12.38 EUR (250) |
Ask (Ask size) | 12.58 EUR (250) |
Open | 12.22 EUR |
High | 12.22 EUR |
Low | 12.22 EUR |
Close (prev. day) | 12.44 EUR |
VWAP | 12.08 EUR |
Volume (pcs) | 0 |
Trading volume | 0.00 |
Number of trades | 1 |
Last size | 0 |
Related Futures | 0 |
Related Options | - |
Date | Headline | Download | |
2024/07/12 | Global Equity Ratings | ||
2024/06/21 | Global Equity Ratings | ||
2024/06/14 | Global Equity Ratings | ||
2024/05/29 | Global Equity Ratings | ||
2024/04/26 | Global Equity Ratings |
2024/07/16 08:02:11 | |
---|---|
Price | |
12.22 EUR | |
Difference | -1.77% (-0.22) |
ISIN | BE0003766806 |
Symbol | IBAB |
Exchange | Frankfurt |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 365 EUR |
Benchmark | BEL 20 INDEX |
Bid (Bid size) | 12.38 EUR (250) |
Ask (Ask size) | 12.58 EUR (250) |
Open | 12.22 EUR |
High | 12.22 EUR |
Low | 12.22 EUR |
Close (prev. day) | 12.44 EUR |
VWAP | 12.08 EUR |
Volume (pcs) | 0 |
Trading volume | 0.00 |
Number of trades | 1 |
Last size | 0 |
6m | 1Y | 3Y | |
Perf (%) | +12.68% | -17.07% | -23.87% |
Perf (abs.) | +1.40 | -2.56 | -3.90 |
Beta | 1.29 | 0.92 | 0.91 |
Volatility | 43.28 | 39.15 | 39.33 |
Ø price 5 days | Ø volume 5 days (pcs.) | 12.29 EUR (0) |
Ø price 30 days | Ø volume 30 days (pcs.) | 12.93 EUR (122) |
Ø price 100 days | Ø volume 100 days (pcs.) | 12.63 EUR (62) |
Ø price 250 days | Ø volume 250 days (pcs.) | 11.55 EUR (68) |
YTD High | date | 14.38 EUR (2024/05/20) |
YTD Low | date | 9.35 EUR (2024/03/01) |
52 Weeks High | date | 15.04 EUR (2023/07/18) |
52 Weeks Low | date | 8.33 EUR (2023/10/16) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Tradegate | 2024/07/16 | 18:22 | 12.58 EUR | 0.00 | 3 |
Stuttgart | 2024/07/16 | 13:33 | 12.44 EUR | 0.00 | 2 |
Munich | 2024/07/16 | 08:08 | 12.46 EUR | 0.00 | 1 |
London Stock Exchange European Trade Reporting | 2024/07/16 | 17:30 | 12.57 EUR | 0.00 | 2 |
Frankfurt | 2024/07/16 | 08:02 | 12.22 EUR | 0.00 | 1 |
FINRA other OTC Issues | 2024/06/20 | 17:11 | 15.00 USD | 0.06 | 2 |
Euronext Brussels | 2024/07/16 | 17:35 | 12.52 EUR | 0.19 | 154 |
Duesseldorf | 2024/07/16 | 08:11 | 12.26 EUR | 0.00 | 1 |
Berlin | 2024/07/16 | 19:33 | 12.54 EUR | 0.00 | 15 |
ION BEAM APPLICATIONS SA |
- - |
3, chemin du Cyclotron - 1348 Louvain-la-Neuve |
Telefon: +32-1-047-58-11 |
Fax: +32-1-047-58-10 |
E-mail: info-worldwide@iba-group.com |
Ion Beam Applications SA engages in the design, manufacture, and marketing of cancer treatment and diagnosis equipment. It operates through the Proton Therapy and Other Accelerators; and Dosimetry segments. The Proton Therapy and Other Accelerators segment include development, fabrication, and services associated with medical and industrial particle accelerators and proton therapy systems. The Dosimetry segment comprises activities that offer a full range of solutions and services that maximize efficiency and minimize errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company was founded by Yves Jongen on March 28, 1986 and is headquartered in Louvain-la-Neuve, Belgium. |
Olivier Legrain | Chairman of Managing Board |
Frédéric Nolf | Member of Executive Committee |
Soumya Chandramouli | Member of Executive Committee |
Yves Jongen | Member of Executive Committee |
Pierre Mottet | Chairman of Supervisory Board |
Hedvig Hricak | Member of Supervisory Board |
Richard Hausmann | Member of Supervisory Board |
Christine Dubus | Member of Supervisory Board |
Marcel Miller | Member of Supervisory Board |
Sybille van den Hoven | Member of Supervisory Board |
Yves Jongen | Member of Supervisory Board |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer